MedTrace Logo

Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

NCT07508254 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.

The main questions it aims to answer are:

* Does triple therapy result in greater reduction in LDL-C compared to dual therapy?
* What adverse effects occur in participants receiving triple therapy?

Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels.

Participants will:

* Receive either dual or triple lipid-lowering therapy for 3 months
* Attend regular follow-up visits for clinical assessment and laboratory testing
* Undergo lipid profile evaluation at baseline and at the end of the study

Conditions

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet

Atorvastatin administered orally once daily as part of lipid-lowering therapy

DRUG

Ezetimibe 10 mg

Ezetimibe administered orally once daily to reduce cholesterol absorption

DRUG

Bempedoic Acid 180 MG Oral Tablet

Bempedoic acid administered orally once daily as an adjunct lipid-lowering agent

Sponsors & Collaborators

  • Punjab Institute of Cardology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-10-01
Completion
2026-10-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07508254 on ClinicalTrials.gov